Q3 Earnings Forecast for Vitalhub Issued By Stifel Canada

Key Points

• Stifel Canada predicts Vitalhub Corp. will report $0.03 earnings per share for Q3 2025, maintaining a "Strong-Buy" rating on the stock.
• Several analysts have set a price target of C$15.00 for Vitalhub, with the company receiving a consensus rating of "Buy" and a target price of C$14.86.
• Recent insider selling includes Director Danny Matlow disposing of 150,000 shares for approximately C$1.91 million, indicating a 22.39% reduction in his ownership.

Vitalhub Corp. (TSE:VHI - Free Report) - Stock analysts at Stifel Canada issued their Q3 2025 earnings per share estimates for Vitalhub in a report released on Tuesday, October 14th. Stifel Canada analyst J. Keywood forecasts that the company will post earnings per share of $0.03 for the quarter. Stifel Canada has a "Strong-Buy" rating on the stock. The consensus estimate for Vitalhub's current full-year earnings is $0.23 per share. Stifel Canada also issued estimates for Vitalhub's Q4 2025 earnings at $0.02 EPS, FY2025 earnings at $0.11 EPS, Q1 2026 earnings at $0.04 EPS, Q2 2026 earnings at $0.04 EPS, Q3 2026 earnings at $0.05 EPS, Q4 2026 earnings at $0.06 EPS and FY2026 earnings at $0.18 EPS.

VHI has been the topic of a number of other reports. Royal Bank Of Canada set a C$15.00 price target on Vitalhub and gave the company a "moderate buy" rating in a research note on Thursday, September 18th. Raymond James Financial lifted their price target on Vitalhub from C$14.50 to C$15.00 and gave the company an "outperform" rating in a research note on Tuesday, August 12th. Stifel Nicolaus set a C$15.00 price target on Vitalhub and gave the company a "buy" rating in a research note on Wednesday. Scotiabank lifted their price target on Vitalhub from C$14.00 to C$14.50 and gave the company an "outperform" rating in a research note on Friday, June 20th. Finally, National Bankshares set a C$16.00 price objective on Vitalhub and gave the stock an "outperform" rating in a research report on Thursday, August 21st. Two analysts have rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of C$14.86.

Vitalhub Stock Down 2.1%

TSE:VHI opened at C$10.47 on Friday. The stock's 50-day simple moving average is C$11.83 and its 200 day simple moving average is C$11.34. The firm has a market capitalization of C$657.83 million, a PE ratio of 130.88, a price-to-earnings-growth ratio of 1.18 and a beta of 0.62. Vitalhub has a twelve month low of C$8.50 and a twelve month high of C$14.64.

Insider Activity at Vitalhub

In other news, Director Steve Garrington sold 20,000 shares of the business's stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of C$12.90, for a total transaction of C$258,000.00. Following the completion of the sale, the director owned 60,000 shares in the company, valued at C$774,000. The trade was a 25.00% decrease in their ownership of the stock. Also, Director Danny Matlow sold 150,000 shares of the business's stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of C$12.75, for a total value of C$1,912,500.00. Following the sale, the director owned 520,001 shares of the company's stock, valued at approximately C$6,630,012.75. This represents a 22.39% decrease in their position. Insiders own 18.57% of the company's stock.

Vitalhub Company Profile

Vitalhub Corp is Canada-based firm that develops technology solutions for health and human services providers in the mental health (child through adult), long term care, community health service, home health, social service, and acute care sectors. Its technologies include blockchain, mobile, patient flow, web-based assessment, and electronic health record solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.